Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors

Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors

Background Targeting epidermal growth factor receptor (EGFR) has become a strategic approach in cancer therapy, using various modalities including chimeric antigen receptor (CAR)-αβT cell therapies. Despite significant advancements in autologous CAR-αβT cell therapies in B-cell lymphoma, current cel...

Full description

Saved in:
Bibliographic Details
Main Authors: Yi-Chiu Kuo, Hao-Kang Li, Tai-Sheng Wu, Ying Ru, Chia-Yun Lee, Pei-Ju Leng, Yi-Chun Hsieh, Yun-Jung Chiang, Zih-Fei Cheng, Yan-Liang Lin, Shih-Chia Hsiao, Sai-Wen Tang
Format: Article
Language:English
Published: BMJ Publishing Group 2025-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/7/e010500.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/7/e010500.full

Similar Items